Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Lamivudine + Chemoimmunotherapy for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Buffalo, New York
This trial studies if adding lamivudine to standard treatment can help patients with advanced small cell lung cancer. Lamivudine may prevent cancer cells from becoming resistant, while the standard treatment kills the cells and boosts the immune system.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service